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Abstract
Background: With the completion of the human genome sequence the functional analysis and characterization of the encoded
proteins has become the next urging challenge in the post-genome era. The lack of comprehensive ORFeome resources has
thus far hampered systematic applications by protein gain-of-function analysis. Gene and ORF coverage with full-length ORF
clones thus needs to be extended. In combination with a unique and versatile cloning system, these will provide the tools for
genome-wide systematic functional analyses, to achieve a deeper insight into complex biological processes.
Results:  Here we describe the generation of a full-ORF clone resource of human genes applying the Gateway cloning
technology (Invitrogen). A pipeline for efficient cloning and sequencing was developed and a sample tracking database was
implemented to streamline the clone production process targeting more than 2,200 different ORFs. In addition, a robust cloning
strategy was established, permitting the simultaneous generation of two clone variants that contain a particular ORF with as well
as without a stop codon by the implementation of only one additional working step into the cloning procedure. Up to 92 % of
the targeted ORFs were successfully amplified by PCR and more than 93 % of the amplicons successfully cloned.
Conclusion: The German cDNA Consortium ORFeome resource currently consists of more than 3,800 sequence-verified
entry clones representing ORFs, cloned with and without stop codon, for about 1,700 different gene loci. 177 splice variants
were cloned representing 121 of these genes. The entry clones have been used to generate over 5,000 different expression
constructs, providing the basis for functional profiling applications. As a member of the recently formed international ORFeome
collaboration we substantially contribute to generating and providing a whole genome human ORFeome collection in a unique
cloning system that is made freely available in the community.
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Background
Recent efforts have completely unravelled also the human
genome sequence [1-6]. Since, attention has shifted
towards the detailed understanding of gene functions in
health and disease by analysing the structure, biological
activities and dynamics of the encoded proteins. To this
end, RNA interference (RNAi) has received much atten-
tion as a powerful tool for systematic loss-of-function
genetic studies on a large scale [7-9]. However, for many
functional genomics and proteomics applications includ-
ing studies on protein subcellular localization [10], pro-
tein structures [11,12], protein functions in cell-based
experiments [13,14], analysis of protein-protein interac-
tions [15,16], and disease-related processes [17,18],
expression clones are indispensable. The clones of cDNA
collections [2,5,6,19] are generally not ideal for immedi-
ate use in these experiments, as they contain 5'and
3'untranslated regions (UTRs) of varying lengths. These
interfere with the expression of the encoded proteins espe-
cially when coexpression of in-frame fusions with specific
tags at either ends are anticipated. The 5'UTRs may con-
tain in-frame stop codons or lead to the inclusion of arti-
ficial amino acid sequences. The native stop codon that
terminates any ORF furthermore impedes the expression
of C-terminal protein fusions. In consequence, the gener-
ation of clone collections that only contain the protein
coding part of the genes (ORFs) has become a key compo-
nent for the comprehensive and systematic analysis of
protein functions in many different systems. Despite the
availability of the human genome sequence, a respective
full-ORF clone collection is far from being complete [20].
This is in part due to the fact that the structures of many
genes are still unclear, and thus require considerable man-
ual and individual verification [21]. Furthermore, the
phenomenon of alternative splicing has not received
much attention in ORF clone collections yet. Here, we
report on the production of a full-length ORF clone
library of human genes and splice forms, using the recom-
bination-based Gateway cloning system (Invitrogen) [22].
We have developed a cloning approach applied to more
than 2,200 different ORFs including (1) optimization and
improvement of gene models, and of the ORF amplifica-
tion and cloning processes, (2) development of a cloning
strategy to simultaneously generate Gateway entry clones
with and without stop codon, (3) establishment of a pipe-
line for ORF sequence validation (4) programming and
implementation of a sample tracking database. The gener-
ated entry clone resource currently comprises more than
3,800 sequence-validated Gateway clones for more than
1,850 ORFs, the coding sequences have an average size of
greater 2 kb. As a member of the recently initiated interna-
tional ORFeome collaboration [20] we significantly con-
tribute to generating and providing ORF clone resources
for all human genes and their splice forms in a unique and
flexible cloning system. The Gateway entry clones have
since been used to generate over 5,000 different expres-
sion constructs that have been successfully exploited in
functional profiling applications [13,14,23,24]. All entry
clones are available through the international ORFeome
collaboration [25].
Results and Discussion
Gene structures and models
A number of automated software solutions have been
implemented to annotate genomes and genes [26,27].
Also then the quality of gene predictions is tightly associ-
ated with the availability and quality of cDNA sequence
information as most gene predictions are based on cDNA
sequences [27,28]. Nevertheless, automated gene predic-
tions are not perfect, and careful manual annotation is
thus the method of choice in gene structure modeling
[29]. We systematically performed manual annotation of
genes and gene structures using available sequence infor-
mation from mammalian species and computational
gene predictions. The combined data was used to create
gene models and virtual templates, to finally predict func-
tional ORFs for subsequent cloning and sequence valida-
tion. The German cDNA Consortium focuses on the ORF
cloning of genes not yet present in ORF clone collections.
Thus far, some 2,500 gene loci have been annotated, iden-
tifying more than 2,200 full-ORF variants of about 2,000
genes. cDNAs, either annotated as mRNA or ESTs, were
available for more than 1,850 genes (either DKFZ or MGC
clones), while RT-PCR amplification was required for
about 150 gene and ORF-models. These covered mostly
long and lowly expressed genes. Figure 1 shows an exam-
ple of a gene model for which three alternative transcript
starts were predicted in our annotation, all of which have
since been confirmed by sequencing of cloned RT-PCR
products. cDNAs were not available to amplify the ORFs
of that gene.
Efficient ORF amplification procedure
- Tagging the ORFs with Gateway sites
For systematic cloning of the ORFs, the recombination-
based Gateway technology (Invitrogen) was used [22] as
it allows their functional exploitation in a broad range of
expression systems in parallel. Initially, the ORFs had
been amplified by a one-step PCR [10]. Many ORFs then
failed to be amplified due to the length of the primer and
the average success rate was < 75 % (Fig. 2). This effect
increased with increasing ORF size, resulting in a > 30 %
PCR failure rate for ORFs > 3 kb (Fig. 2). Further, the error
rate within the primer sites was unacceptably high in
cloned products because of the difficulty to reliably gener-
ate long oligonucleotides. By the switch to a 2-step PCR
strategy described in [30], according to [31,32] a clear
increase in the PCR success rate of up to 15 % could be
achieved, especially for ORFs > 3 kb (Fig. 2). In addition,
this strategy permitted the use of only one universalBMC Genomics 2007, 8:399 http://www.biomedcentral.com/1471-2164/8/399
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primer set suitable for all second step PCRs, resulting in a
reduction of costs for the shortened ORF-specific primers.
Detailed protocols on this and the other procedures in the
cloning process are available at [33].
- Primer quality and processivity and fidelity of DNA polymerases
Although the primer truncation strongly reduced the PCR
failure rate, we still observed primer errors when sequenc-
ing the ORF clones rendering the affected clones useless.
The error rate could be further reduced by selecting the oli-
gonucleotides with the highest sequence accuracy identi-
fied in a comparative test of three suppliers (Table 1).
Whereas for two suppliers mostly frame-shift mutations
caused by a high rate of n-1 primers, were observed, only
3 % of primers from a third supplier were incorrect (Table
1). It should be noted, however, that the quality of suppli-
ers is variable and that care should be taken to follow the
success rate over time.
ORFs with continuously increasing size have been cloned
in the course of the project (Fig. 3), now being 2.2 kb on
average. In this context, a high PCR failure and mutation
rate was observed caused by the DNA polymerase used.
We tested two proofreading DNA polymerases mixtures,
that had ranked best in a comparative prescreen with ten
different enzymes (data not shown), and there the Phu-
sion High-fidelity DNA polymerase (Finnzymes) was
identified as the enzyme possessing a high processivity
(Fig. 4) but a 30-fold higher fidelity compared to the sec-
ond enzyme. Hence this enzyme was used for all subse-
quent PCR reactions. It enhanced the success rate
especially of ORFs > 4 kb and ORFs amplified from pri-
mary cDNA up to 15 % (Fig. 2) in combination with the
addition of DMSO, reported to reduce secondary struc-
tures particularly in GC-rich template stretches [34,35]
and the reduction of the extension temperature from 72 to
63°C [36].
Where a PCR fragment of expected size could not be
obtained, a further round of reamplification was under-
taken which was successful in 36 % of these cases (Table
2). The failure rate was especially high when using pri-
mary cDNAs (Table 2). This concerned mainly large and
lowly and/or only rarely expressed genes and even the
pooling of cDNAs from various tissues resulted only in
few cases in a fragment of correct size.
Modeling of gene structures Figure 1
Modeling of gene structures. Screen shot of the UCSC Genome browser displaying a gene that we predicted to be 
expressed in three variant transcripts and that is consequently characterized by three gene models (hp1_2a-c). The gene mod-
els show different transcription start sites, resulting in different N-terminal ends of the encoded proteins. All three models 
could be verified by ORF amplification, cloning, and sequence validation of the resulting entry clones.BMC Genomics 2007, 8:399 http://www.biomedcentral.com/1471-2164/8/399
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However, if the amplification was clone-based and the
expected PCR product was not obtained, the template
DNA was sequence controlled. More than 10 % of all
clones used did not contain the expected insert probably
due to picking or annotation errors, or they did not con-
tain the complete ORFs. If available, the amplification
was repeated with an alternative template which proved
to be efficient for ≥ 78 % of these ORFs (Table 2). Where
the amplification failed due to no priming or mispriming
events, first-step primer redesign generated a PCR frag-
ment in 81 % of the cases (Table 2).
By the application of our PCR pipeline optimized by the
combination of amplification step improvements up to
92 % of the ORFs could be successfully amplified (Fig. 2)
and more than 86 % irrespective of the ORF size (upper
limit tested: 6.5 kb) (Fig. 2; Table 2). We successfully gen-
erated amplicons for a total of 1997 different ORFs (Table
2) which were subsequently subjected to BP cloning.
Recombinatorial cloning of target ORFs
When cloning the ORFs into Gateway entry donor vectors,
we identified the DNA purity as a critical parameter in the
cloning process. Unspecific side-products, often short
contaminations which were particularly observed when
the ORFs had been amplified via RT-PCR, recombined
during the BP reaction more efficiently than the desired
PCR products. This effect increased with larger ORF sizes.
The recombination success rate could be improved by
more than 15 % by gel-purification of the ORFs, proved to
be most advantageous, especially for ORFs > 3 kb com-
pared to ethanol precipitation or even column-purifica-
tion (Fig. 5).
In addition, the BP cloning was as more efficient as more
balanced the molar ratio of PCR product and donor vector
was (1:1), or even was shifted in favor of the PCR product.
This turned out to be a challenge particularly for low
yields of purified PCR products and for ORFs > 2 kb being
amplified from primary cDNA, as uneven ratios resulted
in only few clones mostly containing only the empty
donor vector. Pooling multiple PCR reactions prior to BP
cloning improved the success rate by about 20 % (Fig. 5)
and was superior to raising the cycle number per reaction
as this would have led to increased error rates. The BP
cloning efficiency was further enhanced by replacing the
Gateway donor vector pDONR201 with the "second-gen-
eration" pDONR221 (Fig. 5) reported to improve the
recombination efficiency due to modifications of the
attP1 and attP2 site [37]. In total, more than 1,800 ampli-
cons were successfully cloned (Table 3), thus reaching a
BP cloning success rate of 93 % (Table 3).
Simultaneous generation of ORF clones with and without 
a stop codon
Depending on the downstream applications the native
stop codon of an ORF is required to be present or to be
omitted in the cloning process, to allow for N- and/or C-
terminal fusions, respectively. Localization studies
employing fusion proteins with GFP have shown that pro-
teins harbouring N-terminal leader sequences frequently
mislocalize when they contain an N-terminal extension
[10,38]. In contrast, expression of native proteins e.g. for
protein structure determination [11,12] requires the pres-
ence of the native stop codon. To circumvent the labori-
PCR-success with and without optimization of the reaction  conditions Figure 2
PCR-success with and without optimization of the 
reaction conditions. The impact of the optimizations steps 
on the success rates (in percentages) are shown in depend-
ence on the ORF size. A PCR was defined successful when a 
DNA product of the expected size was observed in analytical 
agarose gel electrophoresis.
Table 1: Comparison of primer quality of three different suppliers
total # of analysed clones % of clones with 
frame shift mutations
% of clones with 
missense mutations
% of positive clones
Supplier 1 100 8 3 89
Supplier 2 100 5 1 94
Supplier 3 100 1 2 97BMC Genomics 2007, 8:399 http://www.biomedcentral.com/1471-2164/8/399
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ous and cost-intensive duplication of all processes during
clone generation and quality control, we developed a
cloning strategy that allows for the simultaneous genera-
tion of two variants of Gateway entry clones, one contain-
ing a particular ORF with and the other without the stop
codon. This was achieved by exchanging the native stop
codon with a degenerated triplet (TGR) at the 3'-end of
the ORF-specific sequence in the reverse PCR primer
sequence leading to the inclusion of an A- or G-residue at
the degenerated position during the PCR (Fig. 6a). The
incorporation of an A-residue results in amplicons that
contain a stop codon (TGA), the inclusion of a G changes
it into a sense codon (TGG) for tryptophan. The primer
design included the combination of that terminal triplet
(TGR) with additional three bases resulting in a BamHI
recognition sequence only if the G was present, whereas
the inclusion of the A destroyed the BamHI site (Fig. 6a).
For the nested PCR performed with a universal primer pair
complementary exclusively to the overhangs (including
the degenerated triplet) common to all first step primers,
reverse primers containing either an A or a G at the degen-
erated position were purchased separately. They were
mixed in a ratio of 1:1 to guarantee an equimolar ratio of
the two primers in the tailed PCR.
For colony-PCR after E.coli transformation the nested PCR
forward primer was used in combination with a reverse
primer designed to anneal 200 bp downstream of the ORF
to the vector backbone (Fig. 6b). PCR products were
digested with BamHI and the absence or presence of the
stop codon was determined by agarose gel electrophoresis
to distinguish the two species of entry clones. Clones with
an open configuration displayed an additional band of
200 bp and a corresponding size shift of the ORF band in
contrast to undigested clones containing a stop codon, as
shown in Fig. 6c.
In summary, with this straightforward cloning protocol
entry clones containing specific ORFs with and without a
stop codon were obtained in parallel, while introducing
only one additional working step, namely the BamHI
Comparison of PCR products amplified with two different DNA polymerase systems Figure 4
Comparison of PCR products amplified with two different DNA polymerase systems. A total of 100 ORFs (50 
ORFs per enzyme mix), ranging from 300 to 4,000 bp in size, were amplified. Electrophoretic analysis of 10 representative 
ORFs amplified using either the supplier I (left panel) or the Phusion™ High-Fidelity DNA Polymerase (Finnzymes) (right 
panel). One-tenth of each reaction product of first and second step ORF amplification were loaded adjacent to each other on 
an analytical agarose gel. According to the lane number the expected ORF sizes and accession numbers of first-step PCR tem-
plates are as follows: 1: 759 bp, BC100921; 2: 1125 bp, BC093648; 3: 1554 bp, BC104948; 4: 3198 bp, BC117368; 5: 651 bp, 
BC105131; 6: 1653 bp, BC109061; 7: 2400 bp, BC113416; 8: 1737 bp, BC117320; 9: 1854 bp, BC101755; 10: 720 bp, 
BC113739.'M' indicates the molecular weight marker lanes.
Average size of ORFs cloned in the project Figure 3
Average size of ORFs cloned in the project. The con-
tinuous increase in the size of successfully cloned ORFs due 
to the combined improvements of ORF amplification and 
cloning procedures is shown with respect to the year.BMC Genomics 2007, 8:399 http://www.biomedcentral.com/1471-2164/8/399
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digest of colony PCR products. The success rate was > 90
% when eight individual entry clones were analyzed for
every ORF. In few cases (< 5 %) only one of the two vari-
ants were found or no ORF (< 5 %) was present in the
clones. Thus, the modification of the ORF flanking region
in the 3'-primer did not significantly influence the recom-
bination efficiency of the BP reaction. This strategy has a
high capacity for automation and can thus be applied in
high-throughput. It enabled the distinction of clones
already before entry clone sequencing, saving the labori-
ous and costly sequencing of randomly selected clones
that would otherwise be required to identify ORF clones
with as well as without a stop codon.
Sequence validation of entry clones
Four entry clones per ORF scored positive by colony-PCR,
two containing and two lacking a stop codon, were sub-
jected to 5' and 3' sequencing using vector primers. The
sequences were analysed for matching the target gene and
for the integrity of the recombination sites to exclude
clones containing primer or recombination errors. If the
clones matched the target sequences the inserts were veri-
fied by complete sequencing using ORF specific primers.
Entry clones were scored positive if the assembled
sequences were identical to the expected sequences or if
they contained base changes that were silent mutations or
confirmed as SNPs. When base changes were observed
that did result in amino acid substitutions they were eval-
uated as follows: If an alternative entry clones was present
containing the correct ORF this clone was further used.
Where amino acid substitutions were detected at different
positions in the clones analysed, further clones were sub-
jected to the sequencing process. If all clones contained
the same amino acid substitutions cloning was repeated
using an alternative template. Clones containing either
nonsense mutations leading to in-frame stop codons or
base changes within the recombination sites which poten-
tially impaired the subcloning efficiency, were rejected. In
cases where the ORF was not present or only partially
cloned due to internal deletions or mispriming events or
where introns were retained, the cloning was repeated. If
the sequencing reaction failed new primers were designed.
Thus far, more than 3,800 entry clones have been
sequence verified encoding more than 1,850 different
ORFs (Table 4), mostly represented by at least one entry
clone with and one without a stop codon (Table 3). The
entry clone sequences are constantly submitted to the
GenBank database. The improvements of particular clon-
ing steps cumulated to our optimized cloning pipeline
Success in entry clone production with and without optimi- zation of the reaction compositions and conditions Figure 5
Success in entry clone production with and without 
optimization of the reaction compositions and condi-
tions. The cumulative effect of the different protocol modifi-
cations on the BP cloning success is shown for different ORF 
size ranges. BP reactions were rated successful when the 
expected ORF could be cloned and sequence verified.
Table 2: Success rates of ORF amplification
template type cDNA clone EST clone primary cDNA total
ORFs targeted # total # posa %b %c # total # posa %b %c # total # posa %b %c # total # posa %b %c
1. amplification 1712 1303 76 76 368 267 73 73 156 39 25 25 2236 1609 72 72
reamplificationd 409 162 40 9 101 39 39 11 117 25 21 16 627 226 36 10
amplified with 
alternative template
103 80 78 5 28 22 79 6 61 15 25 10 192 117 61 5
amplified with 
alternative 1-step 
primers
32 26 81 2 16 13 81 4 21 6 29 4 69 45 65 2
Sum 1712e 1571 92 368e 341 94 156e 85 55 2236f 1997 89
a Number of ORFs with expected product size obtained by PCR.
b Sucess rate of the respective reaction step.
c Contribution of each step to the final PCR success rate (rounded values).
d Reamplification with slight modifications of the PCR protocol depending on result of first amplification.
e Sum of ORFs targeted per template type.
f Total sum of ORFs targetedBMC Genomics 2007, 8:399 http://www.biomedcentral.com/1471-2164/8/399
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Cloning strategy for the simultaneous generation of entry clones in open and closed configuration Figure 6
Cloning strategy for the simultaneous generation of entry clones in open and closed configuration. A: Sequences 
of entry clones 3' of the ORF either containing or not containing a stop codon. The sequences correspond to the reverse 
primer sequences of 2-step PCR. In presence of an A at the degenerated position, a stop codon is created and the BamHI site 
(underlined) destroyed. In contrast, the inclusion of a G generates a BamHI site and results in a translational read-through. B: 
Schematic presentation of the entry clone map. 'for' and 'rev' indicate the binding sites of the colony PCR primers. The degen-
erated position is indicated by the arrow. C: BamHI colony-PCR restriction digest of eight independent colonies resulting from 
BP cloning of four different ORFs amplified using degenerated reverse primers. The arrows mark the additional band which 
appears in presence of the BamHI recognition sequence, indicating that the ORF does not contain a stop codon. ORF 4 con-
tains an internal BamHI site indicated by the appearance of a band of about 100 bp. 'M' indicates the molecular weight marker 
lanes.
Table 3: Success rates of ORF cloning in dependence on the template used
PCR BP reaction Entry clones
ORFs targeted # total # posa %#  p o s b %#  + / -  s t o p  c o d o n c # + stop codond # - stop codone
cDNA clones 1712 1571 92 1477 94 1355 63 55
EST clones 368 341 93 314 92 290 9 13
Primary cDNA 156 85 54 76 89 69 1 3
Sum 2236 1997 89f 1867 93g 1714 73 71
a Number of ORFs with expected product size obtained by PCR.
b Number of ORFs with expected product size detected by colony-PCR of entry clones.
c ORFs represented by at least one sequence verified entry clone with and without a stop codon.
d,e At least one sequence verified entry clone with(d) or without(e) a stop codon was obtained for these ORFs.
f,g Cumulative success rates of PCR reaction (f) and BP cloning (g)BMC Genomics 2007, 8:399 http://www.biomedcentral.com/1471-2164/8/399
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User interfaces of the cloning database "SCISSORS" Figure 7
User interfaces of the cloning database "SCISSORS". A: Screenshot of the data entry sheet of second step ORF PCR. 
B: 96-well colony PCR plate assembled by the software. The entered PCR results are automatically color-coded by the soft-
ware as follows: red and grey: positive or negative colony (presence or absence of a band of expected size on the agarose gel), 
blue: entry clone colonies already used for plasmid preparation, yellow: colonies selected for generation of a new entry clone 
96-well plate. C: User interface of entry clone plates. Clones scored positive in the control digest are automatically color-
coded in green, negative clones remain white. Clicking on the plate positions opens a window to enter the sequencing result of 
the particular entry clone. D: Results of a working step can also be entered in a table format, as shown for the entry clone val-
idation.
Table 4: Overview on sequence validated accepted clones
genes additional splice variants of the 
targeted genes
full-ORFsa
# initially targeted 2021 215 2236
sequence validated clones generated forb 1681 177 1858
% success 83 82 83
a Sum of ORFs encoded by targeted genes and splice variants.
b At least one sequence verified entry clone with and/or without a stop codon was obtainedBMC Genomics 2007, 8:399 http://www.biomedcentral.com/1471-2164/8/399
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thus generating a clone collection which covers > 83 % of
the targeted ORFs (Table 4) thereby an efficiency > 90 was
reached for ORFs up to 2 kb. The clones are distributed via
the ORFeome Collaboration [25] and are made available
through I.M.A.G.E. clone providers.
Database application for sample tracking, standardization 
and quality control
A database application has been developed as a prerequi-
site for the management and monitoring of a high
number of ORFs in parallel and for the tracking of indi-
vidual products in the cloning process. The software has
been designed to automatically generate and maintain a
standardized nomenclature during all steps of the cloning
process, utilizing unique and consistent identifiers for
ORFs, PCR reactions, colony-PCRs, entry- and expression
clones (Fig. 7). Thus, possible errors and inconsistencies
else likely introduced by manual typing could be avoided.
New IDs are generated by the database and subsequent
cloning steps are only enabled after the previous step has
been quality controlled and approved to having been suc-
cessful (Fig. 7a and 7c). All IDs contain a reference to the
ORF models that were named according to the template
used: in case of cDNA or EST clones according to the clone
name and in case of primary cDNA according to the ORF
prediction. Thus, the database implementation guaran-
tees quality standards in the ORF-clone resources and a
full tracking of each product. Working lists for the various
experimental processes can be extracted to follow up on
every particular ORF during the procedure (Fig. 7d). As all
cloning steps have been performed in 96-well format
(PCR, colony-PCR, entry clone preparation and sequence
validation, and downstream processing of the entry
clones), the respective plates could be automatically
assembled by the database application (Fig. 7b and 7c).
This greatly facilitated the automation of the cloning pro-
cedure, as the pipetting sheets could be directly trans-
ferred to the robotic workstations. In consequence, this
contributed significantly to a streamlined cloning proce-
dure and increased the cloning throughput and success
rate. Furthermore, any functional data that are obtained
with the ORF clone resource [13,14,23,24,39] and the cor-
responding expression constructs can be unambiguously
tracked back to entry clones and the material they had
derived from.
Conclusion
We have described the ORF cloning pipeline of the Ger-
man cDNA Consortium, where human full-length ORFs
are manually modelled and annotated, and subsequently
efficiently amplified and cloned into Gateway entry vec-
tors. We have improved and streamlined protocols to cir-
cumvent possible size bias, to simultaneously generate
ORF constructs with and without stop codons, and to
automate most of the processes. SOPs describing the ORF
cloning processes in detail are available at [33]. The Ger-
man cDNA Consortium ORFeome resource currently con-
sists of more than 3,800 sequence-verified entry clones for
more than 1,850 ORF models, most of them cloned with
and without a stop codon. These entry clones represent
about 1,700 genes, 177 splice variants were cloned repre-
senting 121 of these genes. The entry clones allow for a
broad range of subsequent applications to functionally
characterize the ORF encoded proteins in multiple expres-
sion systems in parallel [1,13,14,23,24]. With this
resource we significantly contribute to the international
ORFeome collaboration [20] that aims at the generation
and provision of a whole genome ORFeome collection of
Gateway entry clones. The sequences are available at
EMBL/GenBank/DDBJ databases and the clones are dis-
tributed via the ORFeome Collaboration and are made
available through I.M.A.G.E. clone providers.
Methods
Gene annotation and modeling of new gene structures
Using the UCSC genome browser [40] for visualization,
gene models were built based on mRNA, EST and gene
prediction data. The HUSAR software package [41] was
employed with its BLAST and ORF-prediction tools
mostly for fine analysis and mapping of the gene struc-
tures, and to retrieve data from RefSeq [42] and Entrez-
Gene [43] databases. The UCSC Table Browser function
[44] was used to retrieve relevant sequences for subse-
quent joining to construct full-length ORF models for the
different gene loci. Gene features rendered most relevant
for full-length ORF selection were: EST- and mRNA cover-
age, presence of CpG islands, polyA signals, canonical
splice signals, conservation from comparative genome
data, exclusion of repetitive elements, and not to be target
of nonsense mediated decay (NMD) [27,28]. If functional
alternative splicing was observed for a gene locus different
ORF models were build which were used as reference
sequences for the generation of ORF cloning and sequenc-
ing primers for entry clone sequence verification. For ORF
cloning we selected promising cDNAs or 5'-EST clones
using our DKFZ or the MGC clone resources obtained via
the RZPD (German Resource Center for Genome
Research, Heidelberg). 5'-EST clones were first sequenced
completely to analyze their potential to contain the full
ORF. If no cDNA clones were available, suitable RNA
sources were employed for RT-PCR to amplify full-length
ORFs for subsequent cloning.
ORF amplification by PCR
The amplification of ORFs had originally been performed
in a single PCR reaction as described previously [10], and
has since been replaced by a 2-step procedure [30] per-
formed on 96-well format. Primers for first-step PCR were
designed using the PRIDE program [45] and purchased
salt free from three different suppliers. The standard PCRBMC Genomics 2007, 8:399 http://www.biomedcentral.com/1471-2164/8/399
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contained a final concentration of 1x Phusion HF buffer,
10 ng template DNA, 10 pmol of primers, 0.5 mM dNTPs
and 0.5 U Phusion DNA polymerase in a total reaction
volume of 25 µl. Standard first-step PCR parameters were:
98°C for 30 sec, 12 cycles of 98°C for 10 sec, 55°C for 10
sec, 63°C for 15–30 sec/1 kb, 63°C for 5 min final exten-
sion. The Gateway™ recombination sites were completed
in a second PCR using a universal pair of PAGE-purified
primers (Eurogentec). Forward primer:
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCAC-
CATG; reverse primer: GGGGACCACTTTGTACAA-
GAAAGCTGGGTG (underlined sequences overlap with
primers of first-step PCR). The nested PCR was performed
in a 50 µl reaction volume consisting of 1–5 µl of first PCR
reaction, 10 pmol of primers, 1 mM dNTPs, 1x Phusion
HF buffer and 1 U Phusion DNA polymerase. The stand-
ard cycling conditions were identical to those of the first-
step PCRs. For PCR product purification ethanol precipi-
tation as well as other methods including QIAquick PCR
Purification (Qiagen), ChargeSwitch PCR Clean-Up (Inv-
itrogen), QIAquick Gel extraction (Qiagen) or MinElute
Gel Extraction (Qiagen) were compared for best results.
Detailed protocols for the two-step ORF amplification
process are available at [33].
BP cloning of PCR-products
PCR products were cloned by BP recombination (Invitro-
gen) [22] into pDONR201 or pDONR221 in 96-well for-
mat according to the supplier's instructions, except using
only half of the recommended volumes [22]. Incubation
was at 25°C for 2–20 h. Ca2+-competent DH10B E.coli
bacteria were transformed with the BP product using a
Multiprobe pipetting robot (Perkin Elmer). Transform-
ants were spread in two Q-trays (22 × 22 cm, Genetix),
each subdivided into 48 squares by plastic grids, and con-
taining LB agar supplemented with 50 µg/ml kanamycin.
Eight colonies per ORF were analysed for the presence of
the ORF of expected size in a colony PCR, utilizing the
Perkin Elmer Multiprobe robot to set-up the reactions.
Simultaneously, the colonies were inoculated into a 96
deep well block (Greiner) and bacteria were grown for 16
hours.
Generation of ORF clones in open and closed 
configuration
ORFs both with and without a stop codon were generated
simultaneously by introducing the following protocol
modifications: six additional base pairs (underlined in the
primer sequences below) were added upstream of the
ORF-specific sequence in the reverse PCR primer for the
first PCR step. One of these base pairs represented a
degenerated position (Y = C or T): 5'-TGGGTGGATYCA-
ORF-specific sequence-3'. For the nested PCR two reverse
primers were mixed in an equimolar ratio, each contain-
ing either a "C" or "T" at the degenerated base position of
the first step primer. For entry clone analysis by colony-
PCR the second step ORF-PCR forward primer was com-
bined with the following reverse primer: 5'-TCTTGT-
GCAATGTAACATCAG-3'. Subsequently, the reaction
volume was doubled and 2 units of BamHI were added
directly into the wells of the 96-well colony PCR plate in
order to screen for clones with and without a stop codon.
After 2 h incubation at 37°C the samples were analysed
on agarose gel.
Sequence validation of entry clones
Four entry clones of every ORF two with and two without
a stop codon that had been scored positive in the colony
PCR (Fig. 6c) were rearrayed using the Mulitprobe pipet-
ting robot. Plasmid preparation was done with the Nucle-
ospin Robot-96 plasmid kit (Macherey-Nagel) on the Bio
Robot 9600. Entry clones were subsequently monitored
by BsrGI single and BamHI/PvuI double digest. Clones
scoring positive were subjected to automated sequencing
on 3100 Genetic Analyzers (Applied Biosystems) with
BigDye Terminators v3.1 (Applied Biosystems). The entry
clones were completely sequence-verified including the
Gateway recombination sites applying primer walking
strategy. The primer were designed to aneal every 450 bp
based on the reference sequence of the ORF model using
the PRIDE program [45]. Sequences were assembled using
the Staden package [46] together with the reference ORF
model sequence and checked for differences. Entry clones
sequences were annotated based on the reference
sequences using the Blast tools of the HUSAR software
package [41]. Sequences are constantly submitted to the
GenBank database.
Cloning database
The software for cloning process management ("SCIS-
SORS") is a MS .NET application using MS SQL Server as
a database backend. The software is a Lab Information
Management System (LIMS) providing user interfaces for
working step management, data acquisition and analysis.
It furthermore represents an administration tool for clone
and plate storage and is also used to store and display
clone annotation information.
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